Hepatic Encephalopathy Market Report 2026

The hepatic encephalopathy market size has grown strongly in recent years. It will grow from $1.8 billion in 2025 to $1.89 billion in 2026 at a compound annual growth rate (CAGR) of 5%. The growth in the historic period can be attributed to increasing prevalence of chronic liver diseases, rising alcohol consumption rates, higher incidence of cirrhosis, improved diagnostic awareness, expansion of specialty liver care centers.

The hepatic encephalopathy market size is expected to see strong growth in the next few years. It will grow to $2.38 billion in 2030 at a compound annual growth rate (CAGR) of 6%. The growth in the forecast period can be attributed to growing demand for advanced therapeutics, increasing liver transplant procedures, rising focus on reducing hospitalization rates, expansion of digital monitoring tools, increased investments in hepatology research. Major trends in the forecast period include increasing adoption of targeted drug therapies, growing use of combination treatment regimens, rising focus on early diagnosis and monitoring, expansion of hospital-based treatment protocols, enhanced patient-centric care approaches.

The increasing prevalence of liver diseases is expected to drive the growth of the hepatic encephalopathy market in the coming years. Liver disease is a medical condition that affects the liver and impairs its normal function. Treatments for liver disease, such as those targeting hepatic encephalopathy, can help alleviate symptoms, slow disease progression, improve liver function, and reduce the occurrence of hepatic encephalopathy by managing underlying conditions. This can potentially lower the frequency and severity of episodes while enhancing patients' overall quality of life. For example, according to the Office for Health Improvement and Disparities, a UK government department, hospital admission rates for liver disease rose to 155.2 per 100,000 population (ranging from 152.9 to 157.5) in the financial year ending 2023, up from 150.6 (148.2 to 152.9) the previous year. Therefore, the rising prevalence of liver diseases is driving the hepatic encephalopathy market.

Increasing healthcare expenditures are also expected to support the growth of the hepatic encephalopathy market. Healthcare expenditure refers to the total spending on healthcare services, products, and activities over a specified period, whether at the individual, community, national, or global level. Higher healthcare spending can positively influence hepatic encephalopathy treatment by facilitating advancements in diagnosis, therapy, patient awareness, and overall care. For instance, according to a report by the Office for National Statistics, a UK-based government department, total healthcare expenditure increased by 6.5% in nominal terms between 2023 and 2024, compared with 6.3% growth in 2023. Thus, rising healthcare expenditure is expected to drive the growth of the hepatic encephalopathy market.

Major companies in the hepatic encephalopathy market are focusing on the development of innovative drugs to gain competitive advantages and strengthen their market position. For example, in June 2023, Karolinska Development AB, a Sweden-based pharmaceutical company, developed GR3027 (golexanolone) to treat hepatic encephalopathy. This orally administered small molecule is a GABAA-receptor-modulating steroid antagonist (GAMSA) designed to counteract positive GABAA-receptor modulation caused by endogenous neuroactive steroids. The drug is currently under investigation for hepatic encephalopathy, with trials for CHE being conducted in Phases I/IIa.

Major companies operating in the hepatic encephalopathy market are Salix Pharmaceuticals, Bausch Health Companies, Norgine, Lupin, Sun Pharmaceutical Industries, Dr Reddys Laboratories, Cipla, Teva Pharmaceutical Industries, Mylan, Torrent Pharmaceuticals, Amneal Pharmaceuticals, Zydus Lifesciences, Aurobindo Pharma, Intas Pharmaceuticals, Alkem Laboratories, Alembic Pharmaceuticals, Wockhardt, Hetero Drugs, Cadila Pharmaceuticals, Abbott India.

North America was the largest region in the hepatic encephalopathy market in 2025. The regions covered in the hepatic encephalopathy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hepatic encephalopathy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the hepatic encephalopathy market by increasing costs of imported active pharmaceutical ingredients, diagnostic reagents, and hospital-grade treatment formulations. Healthcare providers in North America and Europe are most affected due to dependence on imported specialty drugs, while Asia-Pacific faces cost pressure on generic drug exports. These tariffs are contributing to higher treatment costs and procurement delays. However, they are also encouraging domestic pharmaceutical production, regional API manufacturing, and improved supply chain resilience for essential liver disease treatments.

The hepatic encephalopathy market research report is one of a series of new reports that provides hepatic encephalopathy market statistics, including hepatic encephalopathy industry global market size, regional shares, competitors with a hepatic encephalopathy market share, detailed hepatic encephalopathy market segments, market trends and opportunities, and any further data you may need to thrive in the hepatic encephalopathy industry. This hepatic encephalopathy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Hepatic encephalopathy is a condition marked by a decline in brain function due to severe liver disease. It is a reversible syndrome of impaired brain function occurring in patients with advanced liver disorders. Management of hepatic encephalopathy (HE) involves treating the underlying liver disease, reducing ammonia levels in the blood, and addressing associated neurological symptoms.

The primary drug classes used to treat hepatic encephalopathy include antibiotics, laxatives, L-ornithine, L-aspartate, and other therapies. Antibiotics help reduce the overall ammonia load in the body, which can contribute to the neurological symptoms of hepatic encephalopathy. These medications can be administered orally, intravenously, or rectally and are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The hepatic encephalopathy market consists of sales of lactulose, neomycin and zinc supplements. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.